Highlights

  • Second quarter total revenues doubled to $360.5 million, including $151.3 million of net sales of Sephience for phenylketonuria.
  • GAAP net income was $83.5 million, or $0.92 per diluted share, versus a prior-year net loss of $64.8 million.
  • Translarna net sales fell to $42.2 million from $59.5 million, and Emflaza declined to $24.6 million from $36.4 million.
  • PTC closed $550.0 million of 0% convertible notes in June and held $2.23 billion of cash, equivalents and marketable securities.

PTC Therapeutics (NASDAQ:PTCT) shares were trading near their 52-week low at USD 62.78 on October 21, 2026, down 0.22%. The rare disease drugmaker filed its second quarter 2026 report on July 30, reporting a $50.0 million milestone from Novartis for starting a Phase 3 votoplam trial and completing a $550.0 million convertible note offering in June.

Based in Warren, New Jersey, PTC Therapeutics is a Delaware corporation describing itself as a global biopharmaceutical company that develops and commercializes medicines for children and adults with rare disorders in neurology and metabolism. Its products include Sephience for phenylketonuria, Translarna and Emflaza for Duchenne muscular dystrophy, and the gene therapy Upstaza/Kebilidi for AADC deficiency. It also receives royalties on Evrysdi for spinal muscular atrophy under its collaboration with Roche and the SMA Foundation.

Sephience Lifts Revenue, Older Products Decline

Total revenues for the quarter ended June 30, 2026 were $360.5 million versus $178.9 million. Net product revenue was $238.8 million, up from $118.3 million, led by Sephience at $151.3 million, of which $127.6 million came from the United States. Translarna net sales were $42.2 million and Emflaza was $24.6 million. Royalty revenue, all related to Evrysdi, was $71.1 million versus $57.6 million, and collaboration and license revenue was $50.6 million, mainly the Novartis milestone.

Income from operations was $149.0 million versus a loss of $35.0 million. Net interest expense rose to $48.5 million from $30.4 million, and the company recorded a $14.0 million income tax expense. For six months, revenues were $633.1 million versus $1.35 billion in 2025, which included $989.2 million of license revenue, and net income was $80.7 million versus $801.7 million.

Regulatory and Competitive Pressures

The filing details several headwinds. Emflaza faces generic competition, and orphan drug exclusivity for patients aged two to under five expired in June 2026. For Translarna, a March 2025 European Commission decision not to renew its conditional authorization in the European Economic Area allows individual countries to permit continued use, and the company said there is a substantial risk it will lose a significant portion of its revenue from the product there. It withdrew its US Translarna application in February 2026 and does not plan further US development for that indication.

For vatiquinone in Friedreich's ataxia, the FDA issued a complete response letter in August 2025 saying an additional well-controlled study would be needed. After meeting the agency again in April 2026, the company plans to begin the open-label PROVE-FA study in the third quarter of 2026.

Capital Structure and Liquidity

The company reported a stockholders' deficit on its balance sheet. In June it closed $550.0 million of 0% convertible senior notes due 2031, receiving about $535.4 million of net proceeds. It used about $328.8 million to repurchase $222.0 million principal of its 1.50% notes due September 15, 2026, leaving $55.5 million outstanding. Operating cash flow for six months was $70.1 million versus $811.8 million, and cash, cash equivalents and marketable securities stood at $2.23 billion. The company also has an at-the-market sales agreement covering up to $125.0 million of common stock, and said it may need substantial additional funding.

Pipeline Milestones Ahead

Novartis started the global Phase 3 trial of votoplam in Huntington's disease in April, planning about 770 participants and including an interim analysis. The company also reported a 24-month interim result from the PIVOT-HD extension study, showing 52% slowing of disease progression at the 10 milligram dose in stage 2 patients versus an external natural history cohort. It expects to begin a Phase 2a study of PTC844 in the third quarter of 2026. The filing gives no numerical financial guidance.